Compare FMBH & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | DBVT |
|---|---|---|
| Founded | 1865 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2014 |
| Metric | FMBH | DBVT |
|---|---|---|
| Price | $42.71 | $20.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $43.40 | $32.04 |
| AVG Volume (30 Days) | 65.2K | ★ 197.0K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 16.06 | 10.26 |
| EPS | ★ 1.06 | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $9.30 | $35.04 |
| Revenue Next Year | $6.66 | $2,360.78 |
| P/E Ratio | $40.40 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $33.67 | $7.53 |
| 52 Week High | $44.85 | $26.19 |
| Indicator | FMBH | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 47.84 |
| Support Level | $42.36 | $18.89 |
| Resistance Level | $42.85 | $21.61 |
| Average True Range (ATR) | 0.94 | 0.81 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 48.18 | 44.92 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.